Lung Transplantation

The answer first

Lung transplantation is the definitive therapy for selected patients with end-stage parenchymal, airway, vascular or suppurative lung disease in whom medical therapy has failed. It is a long-case staple because it forces the candidate to integrate respiratory failure, immunosuppression, opportunistic infection, drug toxicity, malignancy risk and shared decision-making across a transplant timeline measured in years. [1] The 2021 International Society for Heart and Lung Transplantation (ISHLT) registry reported a median adult survival of about 6.7 years after bilateral sequential transplantation, with conditional survival to one year exceeding 9 years — outcomes that justify the programme but mask the relentless attrition from chronic lung allograft dysfunction. [2]

A physician-level answer rests on four pillars: [1]

1. Refer early and list against objective criteria. The common transplant indications are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), pulmonary arterial hypertension (PAH) and non-CF bronchiectasis. Use disease-specific referral and listing thresholds — for IPF, a decline in forced vital capacity (FVC) of 10 percent or a diffusion capacity (DLCO) decline of 15 percent over six months, a 6-minute walk distance below 250 m, an oxygen requirement, or a hospitalisation with respiratory failure should trigger transplant referral. Multi-dimensional scores combining FVC, DLCO, 6-minute walk distance and hospitalisation predict mortality during assessment and help prioritise. [8] In connective tissue disease-associated interstitial lung disease, the ISHLT consensus requires confirmation of extrapulmonary disease control, oesophageal function assessment and cardiac clearance before listing. [1]
2. Allocate organs by acuity, not by waiting time. Most systems now use a Lung Allocation Score (LAS) or composite allocation score that prioritises waitlist urgency (predicted mortality without transplant) and post-transplant survival benefit. The candidate must explain why IPF and CF dominate high-LAS tiers while emphysema patients with lower urgency wait longer — a feature, not a flaw, of the score.
3. Defend the perioperative and early post-transplant plan. Primary graft dysfunction (PGD) is the dominant cause of early mortality. Grade 3 PGD (severe hypoxaemia with PaO2/FiO2 less than 300 or severe radiographic infiltrates) within the first 72 hours predicts both 30- and 90-day mortality and accelerates later chronic rejection. [3]
4. Prevent, detect and treat the long-term killers. Chronic lung allograft dysfunction (CLAD), manifesting as bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS), is the leading cause of late death. A sustained 20 percent fall in FEV1 from baseline defines BOS and is an emergency that demands exclusion of infection, anastomotic stenosis and acute rejection, followed by an azithromycin trial. [7] [10]

DWE high-yield: Three exam-tested facts. First, a sustained 20 percent drop in baseline FEV1 defines BOS after airway, infection and acute rejection are excluded — the FEV1 slope is the most-watched vital sign after transplant. Second, CMV is the commonest and most consequential opportunistic pathogen in lung recipients, and donor-positive/recipient-negative (D+/R-) mismatch carries the highest risk — extended valganciclovir prophylaxis to 12 months reduced CMV disease in the Palmer trial. [6] Third, azithromycin (typically 250 mg three times weekly) reverses BOS in roughly a third of patients by clearing neutrophilic reversible allograft dysfunction (rAD) — the first intervention when FEV1 falls. [7]

References12Show ledgerHide ledger

1. [1]Crespo MM, Lease ED, Sole A, et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. J Heart Lung Transplant, 2021.PMID 34417111
2. [2]Chambers DC, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant, 2021.PMID 34446355
3. [3]Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant, 2017.PMID 28942784
4. [4]Small B, Au J, Brink H, et al. Induction and maintenance immunosuppression in lung transplantation. Indian J Thorac Cardiovasc Surg, 2022.PMID 35756950
5. [5]Humar A, Kumar D, Preiksaitis JK, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant, 2005.PMID 15888055
6. [6]Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med, 2010.PMID 20547904
7. [7]Corris PA, Ryan VA, Small T, et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax, 2015.PMID 25714615
8. [8]Fisher JH, Al-Hejaili F, Kandel S, et al. Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. Respir Med, 2017.PMID 28340864
9. [9]Celik MR, Lederer DJ, Wilt J, et al. Tacrolimus and azathioprine versus cyclosporine and mycophenolate mofetil after lung transplantation: a retrospective cohort study. J Heart Lung Transplant, 2009.PMID 19560698
10. [10]Hao X, Peng C, Lian W, et al. Effect of azithromycin on bronchiolitis obliterans syndrome in posttransplant recipients: A systematic review and meta-analysis. Medicine (Baltimore), 2022.PMID 35839027
11. [11]Gan CT, Ward C, Meachery G, et al. Long-term effect of azithromycin in bronchiolitis obliterans syndrome. BMJ Open Respir Res, 2019.PMID 31673366
12. [12]Wijesinha M, Hirshon JM, Terrin M, et al. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant. JAMA Netw Open, 2019.PMID 31461151